盐酸普拉克索联合多巴丝肼片对帕金森病患者治疗效果、不良反应及生命质量的影响  

Effects of Pramipexole Hydrochloride Combined with Madopa on the Efficacy, Adverse Reactions and Quality of Life of Patients with Parkinson’s Disease

作　　者：赵华[1] 钟丽珍[1] 孙娜[1] 王璐[1] ZHAO Hua;ZHONG Li-Zhen;SUN Na;WANG Lu(Department Two of Neurology,Dalian Central Hospital,Dalian 116033,China)

机构地区：[1]大连市中心医院神经内二科,辽宁大连116033

出　　处：《中国药物经济学》2020年第3期108-111,共4页China Journal of Pharmaceutical Economics

摘　　要：目的探讨盐酸普拉克索联合多巴丝肼片对帕金森病患者治疗效果、不良反应及生命质量的影响。方法选取2016年2月至2019年2月大连市中心医院神经内二科收治的帕金森病患者60例作为研究对象,依据治疗方法不同分为盐酸普拉克索联合多巴丝肼片治疗组(联合治疗组,n=30)和单独多巴丝肼片治疗组(单独治疗组,n=30),比较两组患者的帕金森病评定量表(UPDRS)评分、临床疗效、不良反应发生情况、生命质量。结果治疗前,两组患者UPDRSⅠ、UPDRSⅡ、UPDRSⅢ、UPDRSⅣ、总UPDRS评分比较,差异无统计学意义(P>0.05);治疗后,两组患者的UPDRSⅠ、UPDRSⅡ、UPDRSⅢ、UPDRSⅣ、总UPDRS评分均显著降低,且联合治疗组患者的UPDRSⅠ、UPDRSⅡ、UPDRSⅢ、UPDRSⅣ、总UPDRS评分均显著低于单独治疗组,差异有统计学意义(P<0.05)。联合治疗组患者治疗有效率90.0%(27/30)显著高于单独治疗组70.0%(21/30)(P<0.05),不良反应发生率13.3%(4/30)显著低于单独治疗组26.7%(8/30)(P<0.05)。联合治疗组患者生命质量高比例63.3%(19/30)显著高于单独治疗组26.7%(8/30)(P<0.05),生命质量低比例6.7%(2/30)显著低于单独治疗组40.0%(12/30)(P<0.05),但两组患者生命质量中比例30.0%(9/30)、33.3%(10/30)比较,差异无统计学意义(P>0.05)。结论盐酸普拉克索联合多巴丝肼片对帕金森病患者治疗效果较单独使用多巴丝肼片好,不良反应少,生命质量高。Objective To explore the effects of pramipexole hydrochloride combined with Madopa on the efficacy,adverse reactions and quality of life of patients with Parkinson’s disease.Methods A total of 60 cases of patients with Parkinson’s disease in department two of neurology of Dalian Central Hospital from February 2016 to February 2019 were randomly selected as the study objects,and were divided into 2 groups according to different treatment methods,including pramipexole hydrochloric acid combined with mamoda treatment group(combined treatment group,n=30)and individual Madopa treatment group(separate treatment group,n=30).There was no significant difference in the comparison of UPDRSⅡ,UPDRSⅢ,UPDRSⅣ,and total UPDRS scores(P>0.05).Results After treatment,the UPDRSⅠ,UPDRSⅡ,UPDRSⅢ,UPDRSⅣand total UPDRS scores were significantly lower(P<0.05).The total treatment effective rate of the combined treatment group 90.0%(27/30)was significantly higher than the separate treatment group 70.0%(21/30)(P<0.05),and the incidence of adverse reaction 13.3%(4/30)was significantly lower than the separate treatment group 26.7%(8/30)(P<0.05).The high quality of life ratio of the combined treatment group 63.3%(19/30)was significantly higher than the separate treatment group 26.7%(8/30)(P<0.05),and the low quality of life ratio 6.7%(2/30)was significantly lower than the separate treatment group 40.0%.(12/30)(P<0.05).But comparing the rates of quality of life between the 2 groups,which were 30.0%(9/30)and 33.3%(10/30),there was no statistical significant(P>0.05).Conclusion Pramipexole hydrochloride combined with Madopa is better than modopa alone for patients with Parkinson’s disease,with less adverse reactions and higher quality of life.

关 键 词：盐酸普拉克索 多巴丝肼片 帕金森病 治疗效果 不良反应 生命质量 

分 类 号：R742.5[医药卫生—神经病学与精神病学] R971[医药卫生—临床医学]